Daiichi Sankyo
ASCO22: Enhertu aces key HER2-low test in breast cancer
Phil Taylor
ASCO 2022, AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, Oncology
0 Comment
News/ News/ News/ Oncology/ Sales and Marketing
SEC accuses former AstraZeneca exec of insider trading
Phil Taylor
AstraZeneca, Daiichi Sankyo, Enhertu, insider trading, Kadmon, litigation, Sanofi, SEC
0 Comment
Takeda, Daiichi-backed wearable study planned in Japan
Phil Taylor
Daiichi Sankyo, digital, digital health, Takeda, wearable
0 Comment
Market Access/ News/ News/ News/ Oncology
Enhertu gets breakthrough tag in HER2-low breast cancer
Phil Taylor
antibody-drug conjugate, AstraZeneca, breakthrough Therapy, breast cancer, Daiichi Sankyo, Enhertu, her2, Oncology
0 Comment
Market Access/ News/ News/ News/ Oncology
FDA starts speedy review of Enhertu in lung cancer
Phil Taylor
AstraZeneca, Daiichi Sankyo, Enhertu, her2, Non-small cell lung cancer
0 Comment
News/ News/ Sales and Marketing
Seagen wins Enhertu patent dispute with Daiichi Sankyo
Phil Taylor
antibody-drug conjugate, AstraZeneca, Daiichi Sankyo, Enhertu, patent litigation, Seagen
0 Comment
Big day for AZ, Daiichi as Enhertu aces HER2-low breast cancer trial
Phil Taylor
AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, her2
0 Comment
Daiichi makes play for share of Japan’s COVID booster market
Phil Taylor
coronavirus, COVID-19, COVID-19 vaccine, Daiichi Sankyo, Japan, Omicron
0 Comment